<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
02.06.2020 21:58:00

Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.

(Anzeige)Passende neue Barrier Reverse Convertibles

Analysts can use can the following dial-in instructions to join the call:

Toll Free: 1-888-664-6392
International: 1-416-764-8659
Conference ID: 60945222

Investors can access the live audio webcast at the following link:
https://produceredition.webcasts.com/starthere.jsp?ei=1329530&tp_key=f0dc4775b3

Following the event, the archived webcast will be available on the Company’s website at www.antibethera.com.

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. www.antibethera.com.

Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Nachrichten zu Antibe Therapeutics Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Antibe Therapeutics Incmehr Analysen

Eintrag hinzufügen

Aktien Top Flop

Givaudan 3’588.00
1.38 %
Geberit 486.80
1.10 %
Sika 188.60
1.04 %
Roche Hldg G 333.75
0.97 %
Lonza Grp 532.20
0.95 %
Nestle 105.82
-0.15 %
Alcon 53.54
-0.22 %
LafargeHolcim 42.20
-0.28 %
Swiss Re 73.96
-0.40 %
CS Group 9.79
-0.49 %
Strukturierte Produkte: Beruhigen sich die Märkte? | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News

pagehit